
Although favipiravir showed significant antiviral effects in two phase 3 influenza trials, the clinical efficacy results differed between the trials “for unclear reasons,” researchers reported in The Journal of Infectious Diseases.
“The favipiravir regimen used in the clinical program showed significant antiviral effects in uncomplicated seasonal influenza in both trials, but the primary clinical endpoint — the difference in time to alleviation of a composite of influenza symptoms — did not achieve the 24-hour difference compared to placebo mandated by FDA and was